• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

ChemoCentryx

edit

ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Recent Milestones

edit

• 
  ChemoCentryx received $29.8M in Series D funding. (3/22/07)
  Posted 9/12/09 at 9:14am via venturebeat.com
• 
  ChemoCentryx received $17.7M in Series C funding. (8/24/06)
  Posted 4/22/10 at 12:50am via chemocentryx.com
• 
  ChemoCentryx received $33M in Venture Round funding. (6/17/04)
  Posted 7/23/09 at 8:08pm via chemocentryx.com
• 
  ChemoCentryx added Thomas J. Schall as President, Chief Executive Officer and Chairman of the Board.
  Posted 12/29/12 at 4:56am
• 
  ChemoCentryx added Markus J. Cappel as Chief Business Officer and Treasurer.
  Posted 12/29/12 at 4:57am
• 
  ChemoCentryx added Susan M. Kanaya as Senior Vice President, Finance, Chief Financial Officer and Secretary.
  Posted 12/29/12 at 4:57am

Videos

Screenshots

edit

Above: ChemoCentryx
Uploaded: 7/24/09

Sources

1. ChemoCentryx Raises $33 Million in Private Financing (chemocentryx.com) [edit]
2. ChemoCentryx Completes Series C Financing (chemocentryx.com) [edit]
3. ChemoCentryx, autoimmune disease drug co., raises $29.84M (deals.venturebeat.com) [edit]